The Recent Come Back Of The Pharmacy Stock: Celgene Corporation(NASDAQ:CELG)


Dallas, Texas 04/03/2014 (FINANCIALSTRENDS) –  Jim Cramer of The Street’s has mentioned that there are few pharmacy stocks that despite being new in the business have come back outstandingly. Cramer has also suggested this stock as a must buy. The rating is of course backed up by strong points that the company has which gives the shareholders a chance to witness a better performing stock.

Good performances from company

There are various areas where the company excels and to name a few would be, the excellent growth in the revenue, a significant equity return, decent levels of valuation of the stock, increasing margins of profit and a continuous cash flow in the company from operations. These before mentioned strengths are good enough to have faith in this company.

Analysis given by Jim Cramer in The Street -highlights

–  Celgene Corporation (NASDAQ:CELG)’s revenue has improved a bit as compared to the industry’s average of 14.9%. As compared to the same quarter previous year the revenue has increased by 21.3%. Though this growth appears to be superficial as the company’s earnings per share has not increased accordingly.

–   There is a slight improvement in the return on equity as compared to the same quarter last year. This kind of growth is considered as a boost in the strength of the company. As compared to the other companies in the field of Biotechnology and the average market performance, Celgene Corporation (NASDAQ:CELG)’s return on equity has increased significantly.

–    The profit margins of Celgene Corporation (NASDAQ:CELG) is at present very high of 96.51%.

–   The cash flow in the operations has increased to 12.29% compared to the same quarter previous year. Even if the cash flow has increased, the growth is still going at a slower pace. But overall it is a stock to look forward to and hold after buying it.